Related Experiment Video

Updated: Apr 3, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K

[Polo-like Kinase 1 as a Target for Anti-tumor Therapy]

I Procházková, B Vojtěšek

    Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti
    |September 17, 2015
    PubMed

    Insights

    Polo-like kinase 1 (Plk1) is a key regulator of cell division and a promising cancer target. Inhibitors like Volasertib show therapeutic potential, with new drugs focusing on improved specificity.

    Area of Science:

    • Cell Biology
    • Molecular Oncology
    • Biochemistry

    Background:

    • Polo-like kinase (Plk) family proteins regulate cell cycle and DNA damage response.
    • Plk1, the most studied Plk member, is crucial for mitosis.
    • Plk1 deregulation and elevated levels correlate with poor prognosis in various cancers.

    Purpose of the Study:

    • To explore the therapeutic potential of targeting Plk1 in cancer treatment.
    • To discuss the relationship between Plk1 and p53 protein.
    • To review current and emerging Plk1 inhibitor strategies.

    Main Methods:

    • Literature review and analysis of existing research on Plk1.
    • Discussion of clinical trial data for Plk1 inhibitors.
    • Preclinical evaluation of novel Plk1 targeting strategies.

    Main Results:

    • Plk1 is a validated target for antitumor drug development.
    • Volasertib (BI 6727), an ATP-binding site inhibitor, shows survival benefits in acute myeloid leukemia.
    • Newer Plk1 inhibitors targeting the polo-box domain are under preclinical investigation for enhanced specificity.

    Conclusions:

    • Plk1 is a significant therapeutic target in oncology.
    • Targeting Plk1, particularly with specific inhibitors, offers a promising avenue for cancer therapy.
    • Further development of Plk1 inhibitors, especially those with improved specificity, is warranted.

    More Related Videos

    Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

    Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

    Published on: July 17, 2020

    6.8K
    Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

    Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

    Published on: January 7, 2019

    8.9K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.1K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    1.8K
    PI3K/mTOR/AKT Signaling Pathway01:22

    PI3K/mTOR/AKT Signaling Pathway

    The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
    6.4K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    5.1K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    1.7K
    Inhibition of Cdk Activity02:34

    Inhibition of Cdk Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    6.2K